Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

This study is testing whether adding two drugs — ruxolitinib and decitabine — to the standard preparation regimen before a stem cell transplant can improve outcomes for patients with acute myeloid leukemia (AML). **You may be eligible if...** - You have acute myeloid leukemia and are eligible for a stem cell transplant from a donor - Your leukemia is in first complete remission - You are between 12 and 64 years old - You have a suitable donor (matched sibling, half-matched donor, or unrelated matched donor) - Your liver, kidney, and overall health are in acceptable range **You may NOT be eligible if...** - You have a type of AML called acute promyelocytic leukemia (M3) - You or your donor is pregnant - You have a mental illness that prevents you from following the study - You have uncontrolled infections Talk to your doctor to see if this trial is right for you.